About us Services Careers Contact us Privacy Coripharma secures EUR16.3m in funding 07. Apr 2021 In line with its previously communicated plans, Coripharma has now secured an additional EUR16.3m (ISK2.5bn) in funding to further support its generic pharmaceutical research & development activities and commercial operations. This round of financing brought in strong local venture- & pension funds and an increased holding of many established shareholders. Coripharma is an Icelandic generic pharmaceutical company, built on the solid heritage of the pharmaceutical development and manufacturing site that Coripharma acquired from Actavis / Teva in 2018. The company specializes in B2B services, development, out-licensing, and contract manufacturing for other pharmaceutical companies. Coripharma now offers licenses to 16 generic pharmaceutical products, in different stages of development, with the first product launch scheduled this summer through strong European partners. In the coming years, Coripharma aims to further strengthen its product portfolio by finalizing at least six new developments per year. Jonina Gudmundsdottir, CEO Coripharma: “The added funding will further secure our R&D activities over the coming years as we continue to develop and out-license our pipeline of generic medicines. We’re pleased to experience the confidence shown by the local investment community, both in our team and our business plans.” The Icelandic investment bank Kvika worked with the management team of Coripharma on securing this important milestone in Coripharma’s journey. When you browse on this site, cookies collect data to enhance your experience. Visit our privacy policy (updated 15 APR 2019) and consent tool to learn more, and make choices about the data used. By clicking "Accept" or by continuing to use the site, you agree to this use of cookies and data. Privacy policy Consent tool Accept About us Services Careers Contact us Privacy Coripharma Reykjavikurvegur 78 - 80 220 Hafnarfjordur, Iceland Email info@coripharma.is Phone +354 4206700